Showing results (11-20 of 223) with videos related to
Sort By:
Pageof 23
Neurology. Clinical Practice|January 29, 2021
Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practiceCarrie M Hersh, Haleigh Harris, Devon Conway, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|January 8, 2021
Vascular comorbidity is associated with lower brain volumes and lower neuroperformance in a large multiple sclerosis cohortKathryn C Fitzgerald, Anne Damian, Devon Conway, et al.Journal of Neurology|April 10, 2020
Disease activity outcomes with different washout periods after switching from natalizumab to an alternative disease-modifying therapyLe H Hua, Haleigh Harris, Devon Conway, et al.Current Treatment Options in Cardiovascular Medicine|February 8, 2012
Chronic cerebrospinal venous insufficiency as a cause of multiple sclerosis: controversy and realityClaudiu I Diaconu, Devon Conway, Robert J Fox, et al.Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 14, 2026
Long-term follow-up of patients with multiple sclerosis over age 60: Comparing clinical and radiological outcomes in disease-modifying therapy continuers and discontinuersDaniel R Orme, Eric Matesen, Devon Conway, et al.Muscle & Nerve|September 5, 2002
Clinical variant of familial amyloid polyneuropathyDianna Quan, Jeffrey A CohenAnnals of Neurology|April 27, 2011
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosisJeffrey A Cohen, Jerold ChunExpert Review of Clinical Pharmacology|November 26, 2011
Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720)Daniel Ontaneda, Jeffrey A CohenMultiple Sclerosis (Houndmills, Basingstoke, England)|March 21, 2018
Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60Le H Hua, Tracey H Fan, Devon Conway, et al.CNS Drugs|August 5, 2015
Sphingosine 1-phosphate receptor modulators in multiple sclerosisAdnan M Subei, Jeffrey A CohenPageof 23